UBS Group
FLACW

UBS Group’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

UBS Group’s Portfolio FLACW Stock Details FLACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-158
Closed – – 11529
2022
Q1 		$0 Buy
158
+33
+26% +$14 ﹤0.01% 11395
2021
Q4 		$0 Buy
+125
New +$87 ﹤0.01% 11143

Other funds holding FLACW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32M AUM 108.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

UBS Group's FLACW Position: Q2 2022 in Review

UBS Group sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q2 2022, closing a stake of 158 shares.

UBS Group first reported a position in FLACW in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 30 funds tracked by Wall St. Rank hold FLACW as of Q2 2022.

  • UBS Group reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q2 2022 after selling out during the quarter.
  • UBS Group sold 158 Frazier Lifesciences Acquisition Corporation Warrant shares in Q2 2022.
  • UBS Group first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q4 2021 and held it in 2 quarters.
  • UBS Group's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $0 in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.